MedCost Clear Cost calculator

Drugs / Tremfya

Tremfya cost

guselkumab · Johnson & Johnson. Every official price for Tremfya, side by side, with who pays it.

Short answer

Johnson & Johnson lists Tremfya at $14,566.44 per single SC injection or IV infusion, as of March 2025. Medicare Part B pays up to $66.998 per mg for Tremfya given by IV infusion or injection in a clinic (October 1, 2026 to December 31, 2026). Pharmacies paid an average of $14,620.07–$14,734.21 per pen or syringe (NADAC, Oct 21, 2026). At the FDA label dose of 100 mg at week 0, week 4, then every 8 weeks (an example), one dose (1 × 100 mg pen) comes to $14,566.44 at the list price and $14,620.07 at the average pharmacy acquisition cost. In 2024, Medicare Part D spent $619.0 million on Tremfya, an average of $13,429.83 per prescription fill before rebates (CMS). In Medicare Part D, the yearly out-of-pocket limit is $2,100 in 2026 and $2,400 in 2027.12471056

Source: FDA, Johnson & Johnson, CMS, data.medicaid.gov (NADAC) and Medicare.gov · checked Nov 15, 2026

Tremfya: the official numbers, by situation

PriceAmountWhose price, and who it applies toDate
List price
per single SC injection or IV infusion
$14,566.441 Johnson & Johnson's price to wholesalers (WAC). Most people don't pay it directly. March 2025
Pharmacy cost (NADAC)
one dose: 1 × 100 mg pen (FDA label dose, an example)
$14,620.074 What pharmacies pay on average (CMS survey). Not a patient price. Oct 21, 2026
Medicare Part B payment limit
per mg, Tremfya given by IV infusion or injection in a clinic
$66.9982 What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026

On Medicare drug coverage: 4,690 of 5,492 Part D plans list Tremfya for 2027 (85%), and 98% of those require prior authorization, in CMS's formulary file published Oct 15, 2026.17 By year and tier

None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.

FDA approval

Every official price

PriceAmountWhat it isDate
Maker's list price (WAC) $14,566.441 Per single SC injection or IV infusion. The price the maker charges wholesalers; most people do not pay it directly. March 2025 (checked Oct 22, 2026)
Medicare Part B payment limit
Tremfya given by IV infusion or injection in a clinic (guselkumab) · HCPCS J1628
$66.9982 Per 1 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Pharmacy acquisition cost (NADAC)
Tremfya 100 mg/mL one-press
$14,734.214 Per pen or syringe ($14,734.21 per mL × 1 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Tremfya 100 mg/mL pen
$14,620.074 Per pen or syringe ($14,620.07 per mL × 1 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Tremfya 100 mg/mL syringe
$14,728.424 Per pen or syringe ($14,728.42 per mL × 1 mL). The national average price pharmacies pay to buy it. Oct 21, 2026
Pharmacy acquisition cost (NADAC)
Tremfya 200 mg/2 mL pen
$14,652.204 Per pen or syringe ($7,326.10 per mL × 2 mL). The national average price pharmacies pay to buy it. Oct 21, 2026

These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3

What Tremfya costs at the FDA label dose (example)

In the FDA label section "Plaque Psoriasis", the dose is 100 mg at week 0, week 4, then every 8 weeks.78 We use it only to show the math with official prices. It is an example, not a dosing recommendation: your dose is your doctor's decision, and other uses on the label have other doses.

100 mg pen prices: list price March 2025; NADAC effective Oct 21, 2026. FDA label version 30 (Oct 20, 2026).

PeriodAt list priceAt pharmacy acquisition cost (NADAC)
One dose
1 × 100 mg pen: 1 injection
$14,566.441 $14,620.074
First 52 weeks
7 × 100 mg pen: doses at weeks 0, 4, 12, 20, 28, 36, 44
$101,965.081 $102,340.494

How we count: list price $14,566.44 per single SC injection or IV infusion times the count; NADAC $14,620.07 per 100 mg pen (Tremfya 100 mg/mL pen) times the count. None of these is what you pay at the counter: the list price is what the maker charges wholesalers and NADAC is what pharmacies pay to buy the drug.

What Medicare spent on Tremfya in 2024

CMS publishes what Part D spent on each drug each year. Its spending is the gross drug cost, which includes what Medicare, the plan and the patient paid,11 and it does not reflect manufacturers' rebates.12 CMS lists Tremfya in 2 rows; together they come to $619.0 million over 46,093 prescription fills, $13,429.83 per fill.

Medicare Part D, calendar year 2024 (CMS Medicare Part D Spending by Drug, checked Nov 15, 2026).

Product (as CMS lists it)Total spendingFillsPeoplePer fillPer person
Tremfya Pen $0.2 million10 14 12 $16,895.9013 $19,711.8914
Tremfya*15 $618.8 million10 46,079 10,848 $13,428.7813 $57,041.3514

These are totals and averages across everyone in Medicare who used the drug, not a price for one person. Averages per person depend on how long and how much each person used it.

Medicare Part D spending on Tremfya, 2020–2024

CMS Medicare Part D Spending by Drug, "Tremfya*" (all makers), gross cost before rebates, checked Nov 15, 2026.

YearTotal spendingPrescription fillsPeoplePer fill
2020$167.4 million1814,3553,469$11,660.92
2021$285.3 million1823,0405,687$12,380.71
2022$439.1 million1833,4447,918$13,130.15
2023$531.5 million1838,6228,945$13,761.51
2024$618.8 million1846,07910,848$13,428.78
Per fill = total spending ÷ fills (matches CMS's own average). Totals for everyone in Part D who used it, not a price for one person.

How many Medicare Part D plans list Tremfya

Every Medicare drug plan in CMS's formulary file (standalone drug plans and Medicare Advantage plans with drug coverage). A plan counts when its drug list has at least one form or strength. Matched by RxNorm code and checked against the FDA NDC Directory. Plan counts, not people; to see your own plan's rules use Medicare Plan Finder.

Plan yearPlans that list itPrior auth.Step therapyQuantity limitLowest tier (plans)
2026 4,979 of 5,49616
91%
4,87944,674 tier 1: 142 · tier 2: 1 · tier 4: 50 · tier 5: 4,786
2027 4,690 of 5,49217
85%
4,59344,426 tier 1: 107 · tier 4: 44 · tier 5: 4,539
2026: CMS file 2026_20260916.zip, published Sep 23, 2026 · 2027: CMS file 2027_20261008.zip, published Oct 15, 2026.

Being on a plan's list is not a price: what you pay depends on the tier and your plan. Each plan can divide its tiers in different ways. What prior authorization, step therapy and tiers mean.

With Medicare

With commercial insurance or no insurance

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (18)
  1. “As of March 2025, the list price of TREMFYA® is $14,566.44 per single SC injection or IV infusion.”
  2. “The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
  3. “Out-of-pocket limit Yearly $2,100 (in 2026).”
    Medicare.gov: Medicare costs · as of Oct 23, 2026
  4. “Out-of-Pocket Threshold: $2,100 Out-of-Pocket Threshold: $2,400”
  5. “100 mg administered by subcutaneous injection at Week 0, Week 4, and every 8 weeks thereafter.”
  6. “Injection: 100 mg/mL in a single-dose prefilled pen (TREMFYA PEN).”
  7. “BLA761061 ORIG-1 approved 20170713”
  8. “Tremfya Pen: Tot_Spndng_2024 236542.63, Tot_Clms_2024 14, Tot_Benes_2024 12; Tremfya*: Tot_Spndng_2024 618784543.17, Tot_Clms_2024 46079, Tot_Benes_2024 10848”
  9. “Drug spending metrics for Part D drugs are based on the gross drug cost, which represents total spending for the prescription claim, including Medicare, plan, and beneficiary payments.”
  10. “The Part D spending metrics do not reflect any manufacturers' rebates or other price concessions as CMS is prohibited from publicly disclosing such information.”
  11. “Part D drug spending divided by the number of prescription fills.”
  12. “Total Part D drug spending divided by the number of unique beneficiaries utilizing the drug during the benefit year.”
  13. “' * ' indicates that the average spending per dosage unit reflects multiple routes of administration of the drug”
  14. “Tremfya* | Guselkumab | Overall”

Did this page answer your question?